This library of practical tools and educational resources aims to support UK healthcare professionals in delivering and optimising treatment and care for their pulmonary fibrosis patients.
Simple Dosing and Clear Monitoring
Nutrition booklet
INBUILD® vs INPULSIS®
England ILD Specialist Centres Interactive Map
Sounds of ILDs
HTA guidance
Progressive Pulmonary Fibrosis (PPF) expert videos
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) or by email to PV_local_uk_ireland@boehringer-ingelheim.com.
OFEV® (nintedanib) is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. The recommended dose is one 150 mg capsule taken twice daily.